{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Humphries SE"],"funding":["UCLH NIHR BRC","Astra Zeneca and Schering-Plough Ltd","British Heart Foundation","Medical Research Council","National Institute for Health Research (NIHR)","Pfizer Ltd","Academy of Medical Sciences","NIHR Clinical Lectureship"],"pagination":["41-46"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6013645"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["274"],"pubmed_abstract":["Background and aims
Patients with familial hypercholesterolaemia (FH) have an elevated risk of coronary heart disease (CHD). Here we compare changes in CHD mortality in patients with heterozygous (FH) pre 1992, before lipid-lowering therapy with statins was used routinely, and in the periods 1992-2008 and 2008-2016.Methods
1903 Definite (DFH) and 1650 Possible (PFH) patients (51% women) aged 20-79 years, recruited from 21 lipid clinics in the United Kingdom and followed prospectively between 1980 and 2016 for 67,060 person-years. The CHD standardised mortality ratio (SMR) compared to the population in England and Wales was calculated (with 95% Confidence intervals).Results
There were 585 deaths, including 252 from CHD. Overall, the observed 2.4-fold excess coronary "],"journal":["Atherosclerosis"],"pubmed_title":["Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register."],"pmcid":["PMC6013645"],"funding_grant_id":["CL-2017-21-002","RG008/08","SGL019\\1078","RG3008","MR/K023667/1","ACF-2010-21-012"],"pubmed_authors":["Durrington PN","Capps N","McDowell IFW","Humphries SE","Neil HAW","Soran H","Simon Broome Familial Hyperlipidaemia Register Group","Cooper JA","Jones B","Seed M"],"additional_accession":[]},"is_claimable":false,"name":"Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.","description":"Background and aims
Patients with familial hypercholesterolaemia (FH) have an elevated risk of coronary heart disease (CHD). Here we compare changes in CHD mortality in patients with heterozygous (FH) pre 1992, before lipid-lowering therapy with statins was used routinely, and in the periods 1992-2008 and 2008-2016.Methods
1903 Definite (DFH) and 1650 Possible (PFH) patients (51% women) aged 20-79 years, recruited from 21 lipid clinics in the United Kingdom and followed prospectively between 1980 and 2016 for 67,060 person-years. The CHD standardised mortality ratio (SMR) compared to the population in England and Wales was calculated (with 95% Confidence intervals).Results
There were 585 deaths, including 252 from CHD. Overall, the observed 2.4-fold excess coronary ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jul","modification":"2025-05-29T21:20:45.514Z","creation":"2025-05-29T21:20:45.514Z"},"accession":"S-EPMC6013645","cross_references":{"pubmed":["29751283"],"doi":["10.1016/j.atherosclerosis.2018.04.040"]}}